
Gregory S. Montgomery, MD
Associate Professor of Clinical Pediatrics
Bio
Dr. Gregory Montgomery is an Associate Professor in Clinical Pediatrics at Indiana University School of Medicine. He is also co-Medical Director of the Pediatric Pulmonary Hypertension Program at Riley Hospital for Children. He is a graduate of the Indiana University School of Medicine. Dr. Montgomery completed his pediatric residency at the University of Minnesota and pediatric pulmonary medicine fellowship at the University of Colorado. Dr. Montgomery holds membership in numerous national professional societies including the American Thoracic Society and the Pulmonary Hypertension Association. His Research focuses on improvements in clinical care of children with pulmonary hypertension as well as multicenter collaboration to benefit children with cystic fibrosis.
Titles & Appointments
- Riley Hospital Pulmonary Hypertension Team, Co-Director
Primary work is on investigator-initiated and industry-sponsored clinical studies toward improvements in clinical care of children diagnosed with pulmonary hypertension. Specifically focused on both pharmaceutical interventions as well as therapeutic care pathway optimizations. Also actively work within several international multicenter collaborations investigating novel therapeutic agents to address the underlying physiologic process in patients with cystic fibrosis.
Multifaceted quality improvement initiative to decrease pediatric asthma readmissions.
Preterm respiratory disease in the modern era: the value of cohort studies.
Safety of Adding Salmeterol to Fluticasone Propionate in Children with Asthma.
Official American Thoracic Society technical standards: flexible airway endoscopy in children.
Effect of treatment of cystic fibrosis pulmonary exacerbations on systemic inflammation.
Why exercise capacity does not improve after pulmonary valve replacement.
An infant with pulmonary interstitial glycogenosis: clinical improvement is associated with improvement in the pulmonary diffusion capacity.
Pulmonary limitation to exercise after repair of D-transposition of the great vessels: atrial baffle versus arterial switch.
Randomized controlled trial of fish oil and montelukast and their combination on airway inflammation and hyperpnea-induced bronchoconstriction.
Cystic fibrosis.
Eicosapentaenoic acid is more effective than docosahexaenoic acid in inhibiting proinflammatory mediator production and transcription from LPS-induced human asthmatic alveolar macrophage cells.
Effect of fish oil-derived omega-3 polyunsaturated Fatty Acid supplementation on exercise-induced bronchoconstriction and immune function in athletes.
Bronchodilator response: another piece in the asthma mosaic.
Effects of sildenafil on pulmonary hypertension and exercise tolerance in severe cystic fibrosis-related lung disease.
Pulmonary Hypertension Association